GlassScriptPhysician profile
Vinay R Saxena
NPI 1366433211
$25,913.38
in general payments reported to CMS, 2019-2025
31 companies · $2,706 in 2025
The $2,706 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $983 · 2021: $725 · 2022: $357 · 2023: $8,536 · 2024: $997 · 2025: $2,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,225 · Consulting Fee: $2,813 · Food and Beverage: $2,145 · Travel and Lodging: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,225.00 |
| Consulting Fee | $2,812.50 |
| Food and Beverage | $2,145.07 |
| Travel and Lodging | $1,057.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $7,880.30 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $7,433.37 | 2019 | |
| Octapharma USA, INC. | $3,597.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $1,437.50 | 2025 | |
| Genzyme Corporation | $1,101.09 | 2021-2025 | |
| Celgene Corporation | $962.50 | 2020 | |
| Alexion Pharmaceuticals, INC. | $569.61 | 2022-2025 | Ultomiris |
| Lantheus Medical Imaging, INC. | $400.00 | 2024 | |
| Becton, Dickinson and Company | $400.00 | 2023 | |
| Beone Medicines LTD. | $400.00 | 2025 | |
| Baxter Healthcare | $300.00 | 2019 | |
| Amgen INC. | $253.66 | 2019-2023 | Blincyto |
| Csl Behring | $195.73 | 2019-2025 | Hemgenix, Idelvion |
| Novo Nordisk INC | $162.03 | 2022-2025 | Novoeight, Rebinyn, Novoseven |
| Agios Pharmaceuticals, INC. | $102.37 | 2022-2025 | Pyrukynd |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genetix Biotherapeutics INC | $99.35 | 2025 | Lyfgenia |
| Servier Pharmaceuticals LLC | $73.27 | 2022-2025 | |
| Springworks Therapeutics, INC. | $69.57 | 2025 | Gomekli |
| Adaptive Biotechnologies Corporation | $66.65 | 2024-2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $53.48 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.44 | 2024 | Advate, Vonvendi |
| Medunik USA INC. | $48.09 | 2024-2025 | Siklos |
| Sobi, INC | $46.32 | 2023-2025 | |
| Duchesnay USA Incorporated | $42.22 | 2023 | Siklos |
| Chiesi USA, INC. | $38.41 | 2022 | |
| Fennec Pharmaceuticals, INC. | $24.49 | 2024 | Pedmark |
| Rare Disease Therapeutics, INC. | $23.35 | 2025 | Xromi |
| Uswm, LLC | $23.23 | 2024 | Iwilfin |
| Kedrion Biopharma, INC. | $21.42 | 2023 | Koate, Albuked, Kedrab |
| Global Blood Therapeutics, INC. | $20.73 | 2020 | |
| Btg International INC. | $16.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Saxena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.